Spruce Biosciences (SPRB) Net Margin (2023 - 2024)
Spruce Biosciences (SPRB) posted quarterly Net Margin of 3368.29% for Q4 2024, down 297978.0% year-over-year from N/an in Q1 2024, and down 133.07% quarter-over-quarter from 1445.17% in Q3 2024.
Spruce Biosciences (SPRB) Net Margin (2023 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported Net Margin for 2 consecutive years, with 3368.29% the latest figure, recorded in Q4 2024.
- In Q4 2024, Net Margin fell 297978.0% year-over-year to 3368.29%; the TTM figure through Sep 2025 stood at 6880.2% (down 630715.0% YoY), while the FY2024 annual figure was 1080.7%, down 54124.0% from the prior year.
- Net Margin slipped to 3368.29% in Q4 2024 per SPRB's latest filing, from 1445.17% in the prior quarter.
- Across five years, Net Margin topped out at 388.52% in Q4 2023 and bottomed at 3368.29% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,368.29% |
| Sep 30, 2024 | -1,445.17% |
| Jun 30, 2024 | -570.25% |
| Mar 31, 2024 | -581.25% |
| Dec 31, 2023 | -388.52% |
| Sep 30, 2023 | -446.63% |
| Jun 30, 2023 | -634.82% |
| Mar 31, 2023 | -652.40% |